Executive leader with over fifteen years of experience leading worldwide pre-clinical and clinical programs in oncology, heading multi-disciplinary teams, and managing multi-million-dollar budgets in private and publicly traded companies. CEO of KAHR Medical since 2017, a privately-held biotechnology company developing a novel drug platform based on, bi-functional, immunotherapeutic fusion proteins, targeting multiple cancer indications. Prior to joining KAHR, served as Chief Development Officer at Cellect Biotechnology (NASDAQ: APOP) and as Senior Director of Oncology at BioLineRx (NASDAQ: BLRX). Holds a Ph.D. in Molecular Genetics and Biochemistry from the Tel-Aviv University and was a post-doctoral fellow at Genentech, a leading biotechnology company, member of the Roche Group.